These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 14225879)

  • 21. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 22. Durability of antibodies induced by inactivated measles virus vaccine.
    Masuno S; Kaneko T; Arakawa S
    Zentralbl Bakteriol Orig; 1968 Apr; 206(3):353-60. PubMed ID: 5707315
    [No Abstract]   [Full Text] [Related]  

  • 23. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
    Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
    J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. INACTIVATED MEASLES VIRUS VACCINE SUBSEQUENTLY CHALLENGED WITH LIVE ATTENUATED MEASLES VIRUS VACCINE.
    KIMURA M; ISHIGURO Y
    Jpn J Med Sci Biol; 1965 Feb; 18():65-71. PubMed ID: 14300296
    [No Abstract]   [Full Text] [Related]  

  • 25. CLINICAL AND SEROLOGICAL OBSERVATIONS ON THE CHILDREN GIVEN ATTENUATED MEASLES VACCINE.
    ARAI M; NAKAMURA M; AKAMATSU T; KIMURA M; KITAYAMA T; KOIDE G
    Acta Paediatr Jpn; 1963 Dec; 14():9-16. PubMed ID: 14200614
    [No Abstract]   [Full Text] [Related]  

  • 26. SIMULTANEOUS ADMINISTRATION OF ORAL POLIO VACCINE AND GLOBULIN-MODIFIED ATTENUATED MEASLES-VIRUS VACCINE.
    FROESCHLE JE; CASEY H
    J Pediatr; 1965 Jun; 66():1031-4. PubMed ID: 14288455
    [No Abstract]   [Full Text] [Related]  

  • 27. GLOBULIN-MODIFIED VACCINATION WITH LIVE ATTENUATED MEASLES VIRUS, SUGIYAMA, ADAPTED TO BOVINE RENAL CELLS.
    MINAMITANI M; NAKAMURA K; SHINOZAKI T; TAKAHASHI T; FUJII R; SABURI Y; MATUMOTO M
    Jpn J Exp Med; 1964 Apr; 34():85-8. PubMed ID: 14171677
    [No Abstract]   [Full Text] [Related]  

  • 28. [Evaluation of the vaccination of a misture of inactivated and live measles vaccines. 1. Clinicoserological observation for a period of 4 years].
    Tanaka H
    Nihon Shonika Gakkai Zasshi; 1972 Mar; 76(3):162-9. PubMed ID: 5065657
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical laboratory experiences with a more attenuated Enders' measles virus vaccine (Moraten) combined with smallpox vaccine.
    Weibel RE; Stokes J; Buynak EB; Leagus MB; Hilleman MR
    Pediatrics; 1969 Apr; 43(4):567-72. PubMed ID: 4304934
    [No Abstract]   [Full Text] [Related]  

  • 30. Observation of the protective effect of live measles vaccines in the first year after vaccination.
    Sejda J; Helcl J; Strauss J
    J Hyg Epidemiol Microbiol Immunol; 1966; 10(3):288-95. PubMed ID: 4161911
    [No Abstract]   [Full Text] [Related]  

  • 31. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VACCINATION AGAINST MEASLES.
    ENDERS JF
    Aust J Exp Biol Med Sci; 1963 Aug; 41():SUPPL467-89. PubMed ID: 14058869
    [No Abstract]   [Full Text] [Related]  

  • 33. [Gelatin particle agglutination (PA) antibody: comparison to neutralizing antibody (NT) and hemagglutination inhibition (HI) antibody and relationship to IgG avidity].
    Saika S; Matsunaga T; Ogawa T; Ichinohe S
    Kansenshogaku Zasshi; 2008 Jul; 82(4):310-6. PubMed ID: 18697482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of UV-inactivated measles virus.
    Zahorska R; Mazur N; Korbecki M
    Zentralbl Bakteriol Orig A; 1978 Jun; 240(4):424-30. PubMed ID: 696055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 36. MEASLES ANTIBODY IN PATIENTS WITH MULTIPLE SCLEROSIS.
    REED D; SEVER J; KURTZKE J; KURLAND L
    Arch Neurol; 1964 Apr; 10():402-10. PubMed ID: 14113464
    [No Abstract]   [Full Text] [Related]  

  • 37. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts.
    Davidkin I; Valle M
    Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of measles vaccination in young malnourished African children].
    Monjour L; Bourdillon F; Froment A; Claudio-Ribeiro D; Fabre M; Chastang C; Gentilini M
    Bull Soc Pathol Exot Filiales; 1984; 77(3):271-7. PubMed ID: 6488419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
    Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
    Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland.
    Pedersen IR; Mordhorst CH; Ewald T; von Magnus H
    Vaccine; 1986 Sep; 4(3):173-8. PubMed ID: 3532604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.